Riverside Company, a global private equity investor focused on the smaller end of the middle market, has announced the acquisition of Geneva-based Actando.
The software and services company Actando is a global learning organization that provides technology-enabled learning solutions to life sciences commercial teams that advance critical skills and capabilities across marketing, omnichannel, sales, key account management, and market Access. The acquisition of Actando by Red Nucleus, a portfolio company of The Riverside Company, strengthens its European footprint and expands its suite of products and services.
Actando’s clients include Abbot, Allergan, AstraZeneca, Boehringer Ingelheim, Biogen, Gilead, Novartis, Novo Nordisk, Pfizer and Sanofi. The company has delivered almost 3,000 programs to over 130,000 learners across 126 countries since its founding in 2013.
Walder Wyss has advised Riverside on this transaction. The team was led by Thiemo Sturny (partner, corporate/m&a, pictured left) and Michael Kündig (senior associate, corporate/m&a, pictured right). Further, it included Dario Galli (associate, corporate/m&a), Michael Kissling (associate, corporate/m&a), Laura Luongo (counsel, employment), Hugh Reeves (managing associate, regulated markets, competition, technology & IP), Camille Tistounet (associate, corporate/m&a), Maurus Winzap (partner, tax), and Janine Corti (counsel, tax).